Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 2 2000
Play
Audio Below:
Most
people have come to the point where they say on the one hand, dose
is still important and this is something that we need to explore
further. But at the same time, I’ve come to the conclusion
that the kinds of regimens that we have been using and the way we
have been using it, – just escalating with G-CSF or just giving
high doses for one course or even two cycles – is not going
to have a dramatic impact. It may have some impact, but it’s
not going to have a dramatic impact – it’s not going to
impact in the way we thought it was. It’s time to go back to
the drawing board. It’s time to re-think the issue. Now, you
know, my own feeling about this is that part of the problem is that
we’re not substantially escalating the dose at the tumor. And
that if chemotherapy is going to have a big impact in the future
and we’re going to grow the effects a lot more, that we need
to somehow get more targeting of the tumor so that we get less chemotherapy
where we don’t want it, that is, normal tissues and more at
the site of the tumor. And that’s where I’ve doing a lot
of my work recently.
Treatment
of advanced, refractory breast cancer with alternating docetaxel
and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating
factor.
Kwasny, W.; Kornek, G.; Haider, K.; Valencak, J.; Ulrich-Pur, H.;
Penz, M.; Lang, F.; Depisch, D., and Scheithauer, W.. Breast Cancer
Research & Treatment. 63(3):235-241, 2000 Oct. In process
Dose-dense
chemotherapy for breast cancer: the story so far.
Hudis, C. (Reprint available from: Hudis C Mem Sloan Kettering Canc
Ctr, Breast Canc Med Serv 1275 York Ave New York, NY 10021 USA)..
British Journal of Cancer. 82(12):1897-1899, 2000 Jun. No abstract
